This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2016-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2018
Title: Hiroaki Yoshizaki: Innovator in Cancer Treatment
Introduction
Hiroaki Yoshizaki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. With a total of 2 patents, his work focuses on the detection and treatment of cancer-related genes.
Latest Patents
Yoshizaki's latest patents include groundbreaking methods for treating cancer by inhibiting the FGFR3/TACC3 fusion protein. The first patent elucidates a polynucleotide as a novel responsible gene for cancer. It provides a method for detecting this polynucleotide and the polypeptide it encodes, along with a detection kit, probe set, and primer set. The invention also offers a pharmaceutical composition for treating cancer, targeting the fusion gene composed of portions of the FGFR3 and TACC3 genes. The second patent similarly aims to detect FGFR3/TACC3 fusion genes, providing essential tools for cancer diagnosis and treatment.
Career Highlights
Hiroaki Yoshizaki is currently associated with Astellas Pharma GmbH, where he continues to advance his research in oncology. His work has been instrumental in developing innovative solutions for cancer treatment, showcasing his dedication to improving patient outcomes.
Collaborations
Yoshizaki collaborates with notable colleagues, including Atsushi Suzuki and Makoto Asaumi. Their combined expertise contributes to the advancement of cancer research and the development of effective therapeutic strategies.
Conclusion
Hiroaki Yoshizaki's contributions to cancer treatment through his innovative patents highlight his role as a leading inventor in the field. His work not only enhances our understanding of cancer genetics but also paves the way for new therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile